GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of Prostate Volume Assist (PVA) urology-based artificial intelligence (AI) software feature. As a global leader in ultrasound-guided solutions in urology, this AI-based software feature is designed to support clinicians in prostate imaging, biopsies and guiding treatment. This new feature assists urologists by offering a solution that improves workflow and quickly captures prostate volume. The added functionality.

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.

GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite

Wipro Limited Sponsored ADR

Wipro GE Healthcare, a joint venture of India's Wipro Enterprises and a wholly owned entity of U.S.-based GE Healthcare , said it would invest 80 billion rupees ($960 million) in the country in its manufacturing and research and development facilities.

Wipro GE Healthcare to invest $960 mln in R&D, manufacturing in India

GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.

GE HealthCare (GEHC) Uses AI Solution to Boost Medical Imaging

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health's nCommand Lite technology. The vendor-agnostic, multi-modality nCommand Lite system will be distributed exclusively by GE HealthCare and will provide remote patient scanning support, remote access for viewing/review of images*, as well as the ability to connect to remote experts who can provide real-time guidance to the licensed technologist operating the scanner. Off-site experts can.

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

GE Healthcare Technologies is expected to experience good revenue and margin growth due to a healthy backlog, improving backlog execution, and strong end-market demand. GEHC's revenue growth will be supported by pent-up demand for procedures, an optimistic outlook for medical sector capital investments in 2024, and an increasing need for AI and digitization in Medtech products. New product innovations and a tuck-in M&A strategy will also contribute to sales growth, and the company is trading at a significant discount to its peers.

GE HealthCare Technologies: Growth Prospects Remain Encouraging, And Valuation Is Attractive

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the first quarter of 2024 payable on May 15, 2024 to all shareholders of record as of April 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics t.

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases and health conditions.

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.

GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Earnings Growth & Price Strength Make GE HealthCare Technologies (GEHC) a Stock to Watch

NVIDIA

SAN JOSE, Calif.--(BUSINESS WIRE)--Building on a long-term artificial intelligence (AI) collaboration, GE HealthCare used NVIDIA technology to develop its recent research model SonoSAMTrack1, which combines a promptable foundation model for segmenting objects on ultrasound images called SonoSAM1. SonoSAMTrack focuses on segmenting anatomies, lesions, and other essential areas in ultrasound images. SonoSAMLite is a streamlined version of SonoSAMTrack. “GE HealthCare is committed to investing in.

GE HealthCare Accelerates AI Innovation with Healthcare-Specific Foundation Models Powered by NVIDIA

GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.

GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow

Deere & Company

Nvidia shares have soared but aren't unreasonably priced. The next wave of stocks to benefit from AI investment is ready to take off.

If You Like Nvidia for Its AI Exposure, Then You'll Love These Two Stocks

HARTFORD, Conn.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and Connecticut-based Hartford HealthCare today announced that they have renewed a seven-year collaboration that began in 2016 to now extend through 2030, aiming to advance the healthcare system's mission to provide personalized coordinated quality care. The Care Alliance strives to assist Hartford HealthCare in increasing access to in.

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, announced the establishment of its philanthropic entity, the GE HealthCare Foundation. The Foundation will operate as a charitable organization, incorporated separately from GE HealthCare, focused on advancing equitable access to precision healthcare. The GE HealthCare Foundation supports nonprofit organizations aimed at making healthcar.

GE HealthCare Establishes the GE HealthCare Foundation

The medical imaging giant announced details of another secondary stock sale.

GE Healthcare Stock Is Tumbling. Why It Should Recover.

GE Healthcare Technologies Inc.'s stock fell 6% in premarket trade Wednesday to lead S&P 500 decliners, after the company announced the pricing of an upsized secondary offering of shares.

GE Healthcare leads early S&P 500 decliners after pricing offering of 14 million shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 14,000,000 shares of its common stock (the “GEHC Shares”). The Offering was upsized from the previously announced offering size of 13,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Share.

GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, Gener.

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares

ORLANDO, Fla.--(BUSINESS WIRE)--Based on its long-term artificial intelligence (AI) partnership, GE HealthCare and Mass General Brigham plan to integrate medical imaging foundation models into their AI research work, with a strong focus on responsible AI practices. Both organizations have been working closely on AI solutions since announcing their 10-year commitment in 2017 to explore the use of AI across a broad range of diagnostic and treatment paradigms through sustainable AI development. “T.

GE HealthCare and Mass General Brigham Evolve Their AI Collaboration with Medical Imaging Foundation Models

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

GE HealthCare Technologies is expected to see profits and cash flows rise in 2024, leading to a potential strong upside for the stock. The company's revenue growth was driven by higher prices and increased volume, with the Pharmaceutical Diagnostics segment performing particularly well. Despite bottom-line issues, the stock is attractively priced relative to similar firms and offers the potential for double-digit returns.

GE HealthCare Technologies' Roar Higher Isn't Over Yet

Apple

General Electric

Victoria's Secret & Co

Microsoft

A strong day for the all but one of the Magnificent 7 stocks fueled upside in the main indexes.

Stock Market Today: Nasdaq Soars as Magnificent 7 Stocks Rally

GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock?

News for GE HealthCare Technologies Inc Stock (GEHC)